2024-2032 年按疫苗类型（肌肉内、鼻内、皮内）、市场类型（公共、私人）和地区分類的 H1N1 疫苗市场报告

2023年全球H1N1疫苗市场规模达37亿美元。展望未来， IMARC Group预计到2032年市场规模将达到55亿美元，2024-2032年复合年增长率（CAGR）为4.2%。日益增长的医疗保健问题、显着的医疗进步、改善的医疗保健系统以及人们对 H1N1 疫苗重要性的认识不断提高是推动市场的一些主要因素。

H1N1 疫苗，也称为甲型流感 (H1N1) 疫苗，旨在提供对 H1N1 流感病毒株的保护。这种病毒株通常被称为“猪流感”，在 2009 年引起了全球大流行。H1N1 疫苗含有灭活或弱化形式的病毒或其成分，促使免疫系统产生针对 H1N1 株的抗体。这些疫苗有助于预防感染并减轻病毒的传播。它们通常包含在季节性流感疫苗配方中，以提供针对 H1N1 以及其他流行流感病毒株的免疫力。

流感大流行的持续威胁凸显了有效疫苗预防 H1N1 病毒传播的重要性，这是推动全球 H1N1 疫苗市场成长的关键因素之一。高传播率和严重疾病的可能性推动了疫苗的需求，以保障公众健康。人们对疫苗接种益处的认识不断增强，以及政府促进免疫计画的措施扩大了疫苗的采用，这进一步促进了市场的成长。公共卫生运动和教育工作也有助于提高疫苗接种率。此外，全球人口的相互联繫加剧了预防措施的必要性。国际旅行和贸易促进了传染病的快速传播，因此需要强有力的疫苗接种策略。此外，製药公司、研究机构和卫生组织之间的合作推动创新并确保及时开发疫苗。监管支持和简化的审批流程鼓励对疫苗研究和生产的投资，这为全球市场创造了积极的前景。

H1N1 疫苗市场趋势/驱动因素：

加强大流行防范

未来疫情的威胁日益严重，促使政府、医疗机构和个人优先考虑疫苗接种作为预防措施，这推动了市场的成长。减少疾病传播和保护弱势群体的需求日益增长，推动了对 H1N1 疫苗的需求。再加上各国政府改善医疗基础设施和增加医疗预算，都促进了市场的成长。

不断增加的公共卫生倡议

世界各国政府和卫生当局越来越多地发起公共卫生运动，以促进疫苗接种并提高人们对影响市场成长的 H1N1 疫苗益处的认识。这些措施的重点是教育大众、消除误解并鼓励积极接种疫苗，以确保广泛预防病毒。这些活动有助于提高疫苗接种率并提高社区免疫力。各国政府也致力于改善公共医疗设施，使最偏远的地区和边缘化群体也能获得这些设施，也促进了疫苗的接种。

全球旅行和互联互通的成长

国际旅行和互联互通的增加促进了 H1N1 等传染病的快速传播，这进一步推动了对 H1N1 疫苗的需求。全球人口的相互连结强调了人口层面的免疫力对于遏制传播的重要性。 H1N1 疫苗为旅客提供保护并降低输入和随后传播的风险，在减少跨境爆发的可能性方面发挥着至关重要的作用。

目录

第一章：前言

第 2 章：范围与方法

• 研究目的
• 利害关係人
• 资料来源
  • 主要资源
  • 二手资料
• 市场预测
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第 3 章：执行摘要

第 4 章：简介

• 概述
• 主要行业趋势

第 5 章：全球 H1N1 疫苗市场

• 市场概况
• 市场业绩
• COVID-19 的影响
• 细分：依疫苗类型
• 细分：依市场类型
• 重点品牌分析
• 细分：按地区
• 市场预测

第 6 章：市场区隔：依疫苗类型

• 肌肉注射
  • 市场走向
  • 市场预测
• 鼻内
  • 市场走向
  • 市场预测
• 皮内
  • 市场走向
  • 市场预测

第 7 章：市场区隔：按类型

• 民众
  • 市场走向
  • 市场预测
• 私人的
  • 市场走向
  • 市场预测

第 8 章：市场区隔：按地区

• 北美洲
  • 市场走向
  • 市场预测
• 欧洲
  • 市场走向
  • 市场预测
• 亚太地区
  • 市场走向
  • 市场预测
• 中东和非洲
  • 市场走向
  • 市场预测
• 拉丁美洲
  • 市场走向
  • 市场预测

第 9 章：重点品牌分析

• 阿格里帕尔
• 菲亚里克斯
• 流感基因
• 流感疫苗
• 纳索瓦茨
• 维克斯握把
• 其他的

第 10 章：SWOT 分析

• 概述
• 优势
• 弱点
• 机会
• 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

• 概述
• 买家的议价能力
• 供应商的议价能力
• 竞争程度
• 新进入者的威胁
• 替代品的威胁

第 13 章：价格分析

• 价格指标
• 价格结构
• 利润分析

第 14 章：产业发展

• 管道和新产品发布
• 併购及合作

第15章：竞争格局

• 市场结构
• 关键参与者
• 关键参与者简介
  • Abbott Laboratories
  • AstraZeneca plc
  • CPL Biologicals Pvt. Ltd
  • CSL Limited
  • Zoetis Inc.

Abstract

The global H1N1 vaccines market size reached US$ 3.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.2% during 2024-2032. The increasing healthcare concerns, significant medical advancements, improving healthcare systems, and rising awareness about the importance of H1N1 vaccines are some of the major factors propelling the market.

H1N1 vaccines, also known as influenza A (H1N1) vaccines, are designed to provide protection against the H1N1 strain of the influenza virus. This strain, commonly referred to as "swine flu," caused a global pandemic in 2009. H1N1 vaccines contain inactivated or weakened forms of the virus or its components, prompting the immune system to produce antibodies against the H1N1 strain. These vaccines help prevent infection and mitigate the spread of the virus. They are typically included in seasonal flu vaccine formulations to offer immunity against H1N1 along with other prevalent influenza strains.

The ongoing threat of influenza pandemics underscores the importance of effective vaccines to prevent the spread of the H1N1 virus which represents one of the key factors driving the growth of the H1N1 vaccines market across the globe. High transmission rates and the potential for severe illness drive the demand for vaccines to safeguard public health. The increasing awareness about vaccination benefits and government initiatives to promote immunization programs amplify vaccine adoption which is further contributing to the market growth. Public health campaigns and educational efforts also contribute to higher vaccination rates. Additionally, the global interconnectedness of populations intensifies the need for preventive measures. International travel and trade facilitate the rapid spread of infectious diseases, necessitating robust vaccination strategies. Furthermore, collaborations between pharmaceutical companies, research institutions, and health organizations drive innovation and ensure timely vaccine development. Regulatory support and streamlined approval processes encourage investment in vaccine research and production which is creating a positive outlook for the market across the globe.

H1N1 Vaccines Market Trends/Drivers:

Rise in pandemic preparedness

The rising threat of future pandemics drives governments, healthcare organizations, and individuals to prioritize vaccination as a preventive measure, which is driving the growth of the market. The increasing need to minimize disease transmission and protect vulnerable populations is fueling the demand for H1N1 vaccines. This, along with improving healthcare infrastructure and increasing healthcare budgets by governments of various nations is contributing to the market growth.

Rising public health initiatives

Governments and health authorities worldwide are increasingly launching public health campaigns to promote vaccination and raise awareness about the benefits of H1N1 vaccines which is influencing the market growth. These initiatives focus on educating the public, dispelling myths, and encouraging proactive vaccination to ensure widespread protection against the virus. These campaigns contribute to higher vaccine uptake rates and improved community immunity. Governments of various nations are also focused on improving public healthcare facilities, making them accessible to even the remotest regions and to the marginalized sections, which is facilitating the uptake of the vaccines.

Rise in global travel and connectivity

Increased international travel and connectivity facilitate the rapid spread of infectious diseases like H1N1 which is further propelling the demand for H1N1 vaccines. The interconnectedness of global populations emphasizes the importance of population-level immunity to curb transmission. H1N1 vaccines play a vital role in reducing the potential for cross-border outbreaks by offering protection to travelers and reducing the risk of importation and subsequent transmission.

H1N1 Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global H1N1 vaccines market report, along with forecasts at the global and regional levels from 2024-2032. Our report has categorized the market based on vaccine type, key brands and market type.

Breakup by Vaccine Type:

Intramuscular

Intranasal

Intradermal

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes intramuscular, intranasal, and intradermal. According to the report, intramuscular represented the largest segment.

Intramuscular vaccines hold a proven track record of eliciting strong and durable immune responses. The muscle tissue provides an optimal environment for antigen presentation, which leads to effective immune activation and antibody production. This enhances the vaccine's ability to confer protection against H1N1 and other influenza strains. Intramuscular injections are a well-established and familiar method in healthcare settings. Healthcare professionals are experienced in administering vaccines via this route, ensuring accurate dosing and proper delivery. The IM route is suitable for a wide range of age groups, from children to adults. This universality makes IM-administered H1N1 vaccines versatile and applicable in mass vaccination campaigns. Intramuscular injections are commonly associated with vaccination, contributing to public acceptance. People are accustomed to receiving vaccines in this manner, leading to fewer barriers and higher compliance rates.

Breakup by Market Type:

Public

Private

A detailed breakup and analysis of the market based on the market type has also been provided in the report. This includes public and private. According to the report, public accounted for the largest market share.

H1N1 vaccines serve crucial roles in public health by providing protection against the H1N1 strain of influenza virus. They help prevent widespread outbreaks by building population immunity, reducing the virus's transmission potential. This safeguards vulnerable individuals, such as the elderly, young children, and those with compromised immune systems. H1N1 vaccines minimize illness severity and related complications, reducing hospitalizations, medical costs, and the burden on healthcare systems. By preventing severe cases, vaccines contribute to overall public health and well-being. The widespread H1N1 vaccination efforts contribute to community immunity or herd immunity, indirectly protecting those who cannot be vaccinated due to medical reasons. This collaborative defense limits the virus's spread within the population. Furthermore, H1N1 vaccines play a pivotal role in pandemic preparedness, as they form the foundation for rapid response to emerging influenza strains with pandemic potential.

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

The report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

In North America, the H1N1 vaccines market is driven by factors, including proactive public health initiatives, well-established vaccination programs, and a strong healthcare infrastructure. The memory of past outbreaks and pandemics, such as the 2009 H1N1 pandemic, has heightened awareness about the importance of vaccination. Robust healthcare systems, accessible medical facilities, and high levels of health literacy contribute to a culture of vaccination. Additionally, government support, regulatory frameworks, and public-private partnerships facilitate timely vaccine development, distribution, and administration. These factors collectively promote the demand for H1N1 vaccines, ensuring preparedness and protection against influenza outbreaks in North America.

Competitive Landscape:

Key players in the H1N1 vaccines market are actively engaged in several strategic initiatives to address the demand for effective vaccines and ensure public health preparedness. These companies focus on continuous research and development (R&D) to create vaccines with enhanced immunogenicity and broader coverage against H1N1 and related strains. Collaborations with research institutions and health authorities enable them to stay informed about evolving virus strains and pandemic potential. Moreover, key players invest in production scalability and efficiency to meet demand during outbreaks. They work closely with regulatory agencies to ensure vaccine safety, efficacy, and timely approvals. In addition, these companies engage in public health advocacy, promoting vaccination through education and awareness campaigns. Furthermore, collaborations with global health organizations, governments, and non-profit entities ensure equitable vaccine distribution, especially in regions with limited access to healthcare. By prioritizing innovation, safety, and accessibility, key players contribute to effective disease prevention and control in the H1N1 vaccines market.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

AstraZeneca plc

CPL Biologicals Pvt. Ltd

CSL Limited

Zoetis Inc.

Recent Developments:

In February 2023, the World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2023-2024 influenza season in the northern hemisphere. The announcement was made at an information session at the end of a 4-day meeting on the Composition of Influenza Virus Vaccines, a meeting that is held twice annually.

In February 2023, the FDA approved these vaccines as a strain change to each manufacturer's seasonal influenza vaccine. There is considerable experience with seasonal influenza vaccine development and production and influenza vaccines produced by this technology have a long and successful track record of safety and effectiveness in the United States. The Influenza A (H1N1) 2009 Monovalent vaccines will undergo the usual testing and lot release procedures that are in place for seasonal influenza vaccines.

In January 2022, with new vaccine targets and more powerful delivery platforms, researchers are making inroads toward an influenza vaccine that could offer better, longer-lasting protection.

In February 2020, Abbott India announced the launch of an inactivated vaccine in India against four strains of influenza virus.

Key Questions Answered in This Report

• 1. What was the size of the global H1N1 vaccines market in 2023?
• 2. What is the expected growth rate of the global H1N1 vaccines market during 2024-2032?
• 3. What are the key factors driving the global H1N1 vaccines market?
• 4. What has been the impact of COVID-19 on the global H1N1 vaccines market?
• 5. What is the breakup of the global H1N1 vaccines market based on the vaccine type?
• 6. What is the breakup of the global H1N1 vaccines market based on the market type?
• 7. What are the key regions in the global H1N1 vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global H1N1 Vaccines Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Breakup by Vaccines Type
• 5.5 Breakup by Market Type
• 5.6 Analysis of Key Brands
• 5.7 Breakup by Region
• 5.8 Market Forecast

6 Market Breakup by Vaccines Type

• 6.1 Intramuscular
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Intranasal
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Intradermal
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Type

• 7.1 Public
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Private
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Analysis of Key Brand

• 9.1 Agripal
• 9.2 Fiuarix
• 9.3 Influgen
• 9.4 Influvac
• 9.5 Nasovac
• 9.6 Vaxigrip
• 9.7 Others

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

• 13.1 Price Indicators
• 13.2 Price Structure
• 13.3 Margin Analysis

14 Industry Developments

• 14.1 Pipeline and New Product Launches
• 14.2 Mergers & Acquisitions and Partnerships

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 AstraZeneca plc
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 CPL Biologicals Pvt. Ltd
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 CSL Limited
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Zoetis Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis

List of Figures

• Figure 1: Global: H1N1 Vaccines Market: Major Drivers and Challenges
• Figure 2: Global: H1N1 Vaccines Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: H1N1 Vaccines Market: Breakup by Vaccines Type (in %), 2023
• Figure 4: Global: H1N1 Vaccines Market: Breakup by Type (in %), 2023
• Figure 5: Global: H1N1 Vaccines Market: Breakup by Region (in %), 2023
• Figure 6: Global: H1N1 Vaccines Industry: SWOT Analysis
• Figure 7: Global: H1N1 Vaccines Industry: Value Chain Analysis
• Figure 8: Global: H1N1 Vaccines Industry: Porter's Five Forces Analysis
• Figure 9: Global: H1N1 Vaccines Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 10: Global: H1N1 Vaccines (Intramuscular) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 11: Global: H1N1 Vaccines (Intramuscular) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 12: Global: H1N1 Vaccines (Intranasal) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 13: Global: H1N1 Vaccines (Intranasal) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 14: Global: H1N1 Vaccines (Intradermal) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: H1N1 Vaccines (Intradermal) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: H1N1 Vaccines (Public) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: H1N1 Vaccines (Public) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: H1N1 Vaccines (Private) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: H1N1 Vaccines (Private) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: North America: H1N1 Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: North America: H1N1 Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Europe: H1N1 Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Europe: H1N1 Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Asia Pacific: H1N1 Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 25: Asia Pacific: H1N1 Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 26: Middle East and Africa: H1N1 Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 27: Middle East and Africa: H1N1 Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 28: Latin America: H1N1 Vaccines Market: Sales Value (in Million US$), 2018 & 2023
• Figure 29: Latin America: H1N1 Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

• Table 1: Global: H1N1 Vaccines Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: H1N1 Vaccines Market Forecast: Breakup by Vaccines Type (in Million US$), 2024-2032
• Table 3: Global: H1N1 Vaccines Market Forecast: Breakup by Type (in Million US$), 2024-2032
• Table 4: Global: H1N1 Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: Global: H1N1 Vaccines Market Structure
• Table 6: Global: H1N1 Vaccines Market: Key Players